Distinguished in Scleredema

Cecilia Varju

1 Akác Street, 
Pecs, BA, HU 
Distinguished in Scleredema
1 Akác Street, 
Pecs, BA, HU 
OverviewLocationsClinical Research

Overview

Cecilia Varju practices in Pecs, Hungary. Ms. Varju is rated as a Distinguished expert by MediFind in the treatment of Scleredema. Her top areas of expertise are Scleredema, Systemic Sclerosis (SSc), Scleroderma, and Stiff Skin Syndrome.

Her clinical research consists of co-authoring 24 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 1 article in the study of Scleredema.

Gender
Female

Locations

1 Akác Street, Pecs, BA 7632, Hungary
Other Locations
Budapest, BU, Hungary

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
Enrollment Status: Terminated
Publish Date: May 16, 2023
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
Enrollment Status: Terminated
Publish Date: January 30, 2023
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Dermatomyositis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Dermatomyositis
Enrollment Status: Completed
Publish Date: August 16, 2022
Intervention Type: Drug
Study Drug: Lenabasum
Study Phase: Phase 3
View 2 Less Clinical Trials

24 Total Publications

Risk factors of cognitive function impairment in patients with systemic sclerosis.
Risk factors of cognitive function impairment in patients with systemic sclerosis.
Journal: Clinical and experimental rheumatology
Published: October 23, 2024

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Varju's expertise for a condition
ConditionClose
    View All 13 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile